Urea transport inhibitors as a new class of diuretics

尿素转运抑制剂作为新型利尿剂

• 批准号: 9248354
• 负责人: ALAN S VERKMAN
• 金额: $ 34.28万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9248354
• 关键词: Acetamides; Animal Model; Animal Testing; Biological Assay; Biological Availability; Cell Culture Techniques; Cell Line; Cells; Chemical Models; Chemicals; Clinical; Congestive Heart Failure; Cytolysis; DDAVP; Data; Dehydration; Development; Diuretics; Drug Kinetics; Edema; Epithelial Cells; Erythrocytes; Fluid overload; Fluorescence; Generations; Goals; Hydration status; Kidney; Kinetics; Knock-out; Knockout Mice; Liquid substance; MDCK cell; Measurement; Metabolic; Modeling; Molecular; Monitor; Nephrotic Syndrome; Oral; Osmolalities; Outcome; Output; Pharmaceutical Preparations; Pharmacology; Physiology; Play; Property; Protein Isoforms; Rattus; Renal function; Research; Rodent Model; Role; Serum; Structure-Activity Relationship; Swelling; Testing; Therapeutic; Toxic effect; Urea; Urine; Vasopressins; analog; assay development; clinical development; clinically relevant; computational chemistry; countercurrent chromatography; high throughput screening; in vivo; inhibitor/antagonist; knockout gene; nitrogen metabolism; novel; public health relevance; scaffold; screening; sensor; tool; transport inhibitor; urea transporter; urinary; water channel

DESCRIPTION (provided by applicant): The generation of a concentrated urine by the kidney involves a countercurrent multiplication mechanism, which is facilitated by urea transporter (UT)-A-type urea transporters in tubule epithelial cells, and a countercurrent exchange mechanism, which is facilitated by UT-B in microvascular (vasa recta) endothelia. Loss of UT function is predicted to disrupt urinary concentrating ability. We propose UTs as novel targets for the development of a new type of diuretic, which we call 'urearetic', with a novel mechanism of action and a unique clinical indication profile. The primary goal of this proposal is to deliver drug-like, validated UT inhibitors for clinical development. Additional deliverables include the generation of potent UT-selective inhibitors as research tools, and, using these tools, to generate new data on renal UT physiology in rodent models by chemical knockout, recognizing its advantages over gene knockout. In Aim 1, a novel high-throughput screen will be used to identify UT inhibitors with different UT isoform selectivity profiles. This aim follows from extensive preliminary data on assay development and identification of UT-B and UT-A1 inhibitors. Screening against each of the major renal UT isoforms, UT-A1, UT-A2 and UT-A3 to identify active compounds for study structure-activity relationships and selectivity profiles will e conducted. In Aim 2, UT inhibition mechanisms and pharmacology of compounds identified in Aim 1 will be determined in order to establish a prioritized list of compounds for animal testing. Target compound properties include high UT inhibition potency (low nM IC50) and good pharmacological profile. Studies will include: (a) using cell culture models - inhibition reversibility, kinetics, sidedness and urea competition; (b) by computational chemistry - the molecular basis of inhibition potency and selectivity; and (c) using rats - pharmacokinetics, renal/urine accumulation and toxicity. In Aim 3, rodent models and UT inhibitors will be used to characterize the role of UTs in urinary concentrating function and to obtain proof-of-concept for UT inhibitor therapy of edema. Target effects of UT inhibitors in vivo include increasing urine output and reducing urinary concentrating ability, and reducing edema in clinically relevant states of fluid accumulation. Studies in rats will include measurements of compound effects on urine output, osmolality and urea concentration, and serum urea concentration, during normal hydration and with dehydration DDAVP. Compound(s) will also be tested in a rat model of edema in congestive heart failure. The outcomes of this proposal will include drug-like, validated UT inhibitors for use as research tools and for clinical development, and new information on the role of UTs in the urinary concentrating mechanism.

描述(申请人提供)：肾脏产生浓缩尿液涉及逆流增殖机制和逆流交换机制，前者由肾小管上皮细胞的尿素转运体(UT)-A型尿素转运体促进，后者由UT-B促进的微血管(Vasa Recta)内皮细胞逆流交换机制。据预测，UT功能的丧失会扰乱尿浓缩能力。我们建议将UTS作为开发一种新型利尿剂的新靶点，我们称之为‘Urearetic’，具有新的作用机制和独特的临床适应症。这项提议的主要目标是实现 用于临床开发的类药物、有效的UT抑制剂。其他成果包括作为研究工具生成有效的UT选择性抑制剂，以及使用这些工具通过化学敲除在啮齿动物模型中生成关于肾脏UT生理学的新数据，认识到其相对于基因敲除的优势。在目标1中，将使用一种新的高通量筛选来鉴定具有不同UT异构体选择性特征的UT抑制剂。这一目标源于大量关于UT-B和UT-A1抑制剂的检测开发和鉴定的初步数据。将针对每个主要的肾脏UT亚型，UT-A1，UT-A2和UT-A3进行筛选，以鉴定活性化合物，以研究结构-活性关系和选择性分布。在目标2中，将确定目标1中确定的化合物的UT抑制机制和药理学，以便建立用于动物试验的化合物的优先列表。目标化合物的特性包括高UT抑制效力(低NM IC50)和良好的药理特性。研究将包括：(A)使用细胞培养模型--抑制可逆性、动力学、侧性和尿素竞争；(B)通过计算化学--抑制效力和选择性的分子基础；(C)使用大鼠--药代动力学、肾脏/尿液蓄积和毒性。在目的3中，将使用啮齿动物模型和UT抑制剂来表征UTS在尿液浓缩功能中的作用，并为UT抑制剂治疗水肿提供概念验证。UT抑制剂在体内的靶向作用包括增加尿量和降低尿液浓缩能力，以及减少临床上相关的液体积聚状态下的水肿。在大鼠身上的研究将包括测量正常水合和脱水DDAVP对尿量、渗透压和尿素浓度以及血清尿素浓度的复合影响。复方(S)还将在充血性心力衰竭的大鼠浮肿模型上进行测试。这项提案的结果将包括用作研究工具和临床开发的类似药物的、经过验证的UT抑制剂，以及关于UTS在尿液浓缩机制中作用的新信息。